http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
신준오,배경남,김훈수,고현창,김병수,김문범,신기혁 대한피부과학회 2022 대한피부과학회지 Vol.60 No.7
Setleis syndrome, also known as the focal facial dermal dysplasia type 3, is characterized by atrophic scar-like lesions in both the temporal regions and other facial abnormalities. The syndrome is associated with a mutation in the TWIST2 gene and is inherited as an autosomal recessive pattern. Here, we describe a case of an 18-year-old woman and her 10-year-old brother with bitemporal depressed patches. The lesions were observed at birth, but they were replaced by atrophic patches after several months. No abnormalities in growth or development were observed. Histopathologic findings showed atrophy of the epidermis and loss of appendages, such as hair follicles and adnexal glands, in the atrophic patches compared to that of the adjacent normal skin.
중등증-중증의 한국인 건선 환자에서 Guselkumab의 효과와 안전성에 관한 연구
신준오,배경남,손진화,신기혁,김훈수,고현창,김문범,김병수 대한피부과학회 2022 대한피부과학회지 Vol.60 No.9
Background: Guselkumab, a human immunoglobulin-G1λ monoclonal antibody, selectively blocks the interleukin-23-mediated signaling pathway. It has emerged as a promising treatment option for moderate-to-severe psoriasis. However, nostudies have reported real-world clinical data on guselkumab in patients with psoriasis in Korea. Objective: To investigate the effectiveness and safety of guselkumab in Korean patients with moderate to severeplaque psoriasis. Methods: We retrospectively reviewed patients with moderate-to-severe psoriasis who were treated with guselkumabat Pusan National University Hospital (Busan and Yangsan) from January 2019 to May 2021. Fifty-six patients withpsoriasis who were treated with guselkumab were included in the study. Patient demographics, psoriasis area andseverity index (PASI) scores, investigator’s global assessment scores, and adverse events were assessed. Results: The mean baseline PASI score (16.2±7.6) significantly decreased after 20 weeks of guselkumab treatment(p<0.05). In total, 76.8%, 78.6%, and 88.1% of patients achieved a PASI90 response at 20, 28, and 52 weeks,respectively. Of 56 patients, 52 had a PASI90 response at the last follow-up visit. No serious adverse events wereobserved. Four patients (7.1%) experienced mild adverse events, such as injection site reaction, upper respiratory tractinfection, and headache. Conclusion: This study reconfirmed the efficacy and safety of guselkumab in Korean patients with moderateto-severe psoriasis.
부분 음영에 따른 a-Si Thin Film Photovoltaic(PV) Module의 직렬저항변화
신준오,정태희,김태범,우성철,윤나리,강기환,한득영,안형근,Shin, Jun-Oh,Jung, Tae-Hee,Kim, Tae-Bum,Woo, Sung-Chul,Yun, Na-Ri,Kang, Ki-Hwan,Han, Deuk-Young,Ahn, Hyung-Keun 한국전기전자재료학회 2010 전기전자재료학회논문지 Vol.23 No.11
PV module has many power loss factors, and series resistance is the most important elements of them. It is therefore easy to expect the partial shading decrease the lifetime of the semiconductor depletion layer in thin film PV module. Different shading losses could be related with the hot spot which is critical in expecting the reliability issue. In this paper we have modelled the series resistance of the PV module with both different direction of the cell line and shading area of the panel. From the results, thin film a-Si PV module has shown different properties by shading direction.